Research & Innovation - Participant Portal

Search

TOPIC : New therapies for chronic diseases

Topic identifier: SC1-PM-09-2016
Publication date: 14 October 2015

Types of action: RIA Research and Innovation action
DeadlineModel:
Opening date:
single-stage
20 October 2015
Deadline: 13 April 2016 17:00:00

Time Zone : (Brussels time)
  Horizon 2020 H2020 website
Pillar: Societal Challenges
Work Programme Year: H2020-2016-2017
Topic Description
Specific Challenge:

Chronic diseases represent a significant burden on individuals and healthcare systems in the European Union and beyond. Innovative and effective therapeutic approaches are required to provide the best quality of care when prevention strategies fail. While considerable basic knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

Scope:

Proposals should focus on clinical trial(s), supporting proof of concept of clinical safety and efficacy in humans[1] of novel therapies (pharmacological as well as non-pharmacological) or the optimisation of available therapies (e.g. repurposing) for chronic non-communicable or chronic infectious diseases. Preclinical research should be completed before the start of the project. Proposals should provide a sound feasibility assessment, justified by available publications or provided preliminary results. Gender and age must be considered whenever relevant. Due consideration should also be paid to involve patients and take their views into account wherever relevant. Rare diseases and regenerative medicine are not within the scope of this topic[2],[3].

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:
  • New or optimised therapeutic strategies, adapted where relevant to the different needs of men, women, children and the elderly, with the highest potential to generate advances in clinical practice and care for chronic non-communicable or chronic infectious diseases.
  • Improve the therapeutic outcome of major chronic health issues with significant impact on disease burden of individual patients and health care systems.
Cross-cutting Priorities:

Gender
Socio-economic science and humanities

[1]Phase 3 and phase 4 clinical trials are excluded.

[2]See topic SC1-PM-08-2017 addressing new therapies for rare diseases.

[3]See topic SC1-PM-11-2016-2017 addressing clinical research on regenerative medicine

Topic conditions and documents

Please read carefully all provisions below before the preparation of your application.
 

  1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
    Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects (follow the links to China, Japan, Republic of Korea, Mexico, Russia, Taiwan, USA).

     
  2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.

    Proposal page limits and layout: Please refer to Part B of the standard proposal template.

     
  3. Evaluation

    3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions: The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.

    3.2 Submission and evaluation process: Guide to the submission and evaluation process

          
  4. Indicative timetable for evaluation and grant agreement:

    Information on the outcome of single-stage evaluation: maximum 5 months from the deadline for submission.
    Signature of grant agreements: maximum 8 months from the deadline for submission.

     
  5. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    Research and Innovation Action:

    Specific provisions and funding rates
    Standard proposal template
    Specific evaluation form
    H2020 General MGA -Multi-Beneficiary
    Annotated Grant Agreement

     
  6. Additional provisions:

    Horizon 2020 budget flexibility

    Classified information

     
  7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

     
  8. Additional documents:

    H2020 Work Programme 2016-17: Health, demographic change and wellbeing

    H2020 Work Programme 2016-17: Dissemination, Exploitation and Evaluation

    H2020 Work Programme 2016-17: General Annexes

    Legal basis: Horizon 2020 - Regulation of Establishment

    Legal basis: Horizon 2020 Rules for Participation

    Legal basis: Horizon 2020 Specific Programme

 

Additional documents

  • Flash Call Info (call results) en

Submission Service

No submission system is open for this topic.

Get support

H2020 Online Manual your online guide on the procedures from proposal submission to managing your grant.

Participant Portal FAQ – Submission of proposals.

National Contact Points (NCP) - 
contact your NCP for further assistance.

Research Enquiry Service
– ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

Enterprise Europe Network
– contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk
- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

Contact the EIT for further assistance related to the call, topics and the content of proposals via the Contact Page on the EIT website.

Clean Sky 2 National Contact Points
- Clean Sky 2 JU States Representative Group

Clean Sky 2 Helpdesk:
Info-Call-CPW-2014-01@Cleansky.EU

ECSEL National Contact Points
– consult Annex G of the ECSEL Work Plan

ECSEL Helpdesk:
setupecsel@ecsel.europa.eu

IMI States Representative Group (SRG)
– contact you SRG member for assistance.

IMI JU IT Helpdesk
– for IMI2 topics contact the SOFIA IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

Shift2Rail Call Helpdesk: info-call@shift2rail.europa.eu

Ethics
– for compliance with ethical issues, see the Participant Portal and Science and Society Portal

European IPR Helpdesk
assists you on intellectual property issues

CEN
and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at research@cencenelec.eu.

The European Charter for Researchers and the Code of Conduct for their recruitment


Partner Search Services
help you find a partner organisation for your proposal

IMI Partner Search Tool
helps you find a partner organisation for your proposal